Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin
Background: The high price is a critical barrier of access to new direct-anting-antiviral (DAA) therapies for hepatitis C for both the patients and the society. Many countries continue to face the challenge of financing such expensive medicines. Such examples include both high-income and middle-inco...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Ubiquity Press
2020
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/a6f2448d5e6a4a14a56c60a6e6a57089 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|